Multiple long-term conditions (MLTCs), also known as multimorbidity, are associated with premature mortality, significant treatment burden for patients and carers, and increased healthcare utilisation.

Multiple long-term conditions (MLTCs) are defined as the coexistence of two or more long-term conditions. However, healthcare systems and research infrastructure are not appropriately configured to address MLTCs. The prevalence and impact of MLTCs also vary by ethnicity, with possible differences in longer-term outcomes.

Living with two or more long-term conditions is associated with poorer health outcomes, including lower quality of life, higher use of healthcare services and increased risk of early death. The role of MLTCs in increased COVID-19 mortality among ethnically diverse groups highlighted these inequalities. Polypharmacy, the use of multiple medicines, is common in people living with MLTCs, but its benefits and harms are not yet fully understood. While taking multiple medicines may be necessary, it can also increase the risk of adverse effects and drug interactions.

Most published research on MLTCs has focused on older populations because of the increased prevalence in this age group. However, the number of people living with MLTCs is higher among those aged under 65 years, highlighting the need for further research in younger adults, where opportunities for intervention may be greater.

Impact at a glance

  • Secured an NIHR AiM Development Grant (£117,200) to establish a research consortium and generate proof-of-principle data;
  • Secured £3.1 million in NIHR funding for the AI-MULTIPLY Research Collaboration programme;
  • Leveraged a further £5.2 million through the NIHR Patient Safety Research Collaboration programme;
  • Generated evidence showing an excess burden of early-onset multimorbidity among socioeconomically deprived and ethnically diverse groups;
  • Increased understanding of the relationship between MLTCs, ethnicity, social deprivation and hospital readmission;
  • Established a dedicated PPIE group of 40 members with lived experience of MLTCs or caring responsibilities;
  • Increased the critical mass of analysts and researchers working on artificial intelligence and multiple long-term conditions;
  • Built a diverse interdisciplinary research community focused on MLTCs across the life course.

Building evidence and research capacity for multimorbidity

Recognising the importance of addressing these challenges, research into MLTCs became a major focus of the NIHR Biomedical Research Centre: Newcastle. Cross-theme support from the BRC contributed to the successful award of an NIHR AiM Development Grant to establish the research consortium and generate proof-of-principle data. This work subsequently led to the successful award of the NIHR AI-MULTIPLY Research Collaboration programme. The AI-MULTIPLY consortium brings together multidisciplinary investigators with a variety of expertise (including health, data science, and social research) across universities, the project PPIE groups, the NHS and Social Action for Health. The overall aim of AI-MULTIPLY is to better understand the complex interactions between MLTCs and polypharmacy and explore how these conditions and medications interrelate and influence people's health across the life course.

A further £5.2 million was leveraged through the NIHR Patient Safety Research Collaboration programme, 'Transforming care and improving safety for patients with multiple long-term health conditions', and the Artificial Intelligence and Data Science theme was jointly led by NIHR BRC: Newcastle and Barts, providing a platform to translate discoveries into patient care and aiming to improve population health.

Early studies have provided insight into the complex relationship between MLTCs and intersectional factors, including ethnicity, social deprivation and hospital readmission. The research demonstrated the excess burden of early onset multimorbidity among socioeconomically deprived and ethnically diverse groups, who are disproportionately and more severely affected by multimorbidity. These findings emphasise the prevalence of multimorbidity in younger age groups and the need to identify, prevent and manage multimorbidity earlier in the life course.

The research also examines how patterns of polypharmacy interact with clusters of long-term conditions and how these combinations influence health outcomes across diverse populations. Artificial intelligence is being used to generate new insights to support safer and more effective care.

The programme has also increased the critical mass of analysts working on artificial intelligence and MLTCs and brought together a diverse interdisciplinary group of researchers to contribute to this field. The consortium has provided interdisciplinary training opportunities, helping to build future capacity in artificial intelligence, health inequalities and public involvement research.

 

Growing a multidisciplinary community

Through these initiatives, the team established an active patient and public involvement and engagement (PPIE) group comprising 40 members with lived experience of MLTCs or caring for someone with MLTCs. Members represent a diverse range of sociodemographic backgrounds, including Bangladeshi, Indian, Asian, Eastern European and Pakistani communities, with representation from locations across the UK.

The PPIE group worked closely with analysts and data engineers and has influenced several aspects of the research. Their input helped shape research questions, supported delivery and dissemination activities, and worked closely with early career researchers, creating a two-way learning environment. Patient and public involvement is embedded throughout the programme.

The initiatives have also increased the critical mass of researchers working on artificial intelligence and multiple long-term conditions and assembled a diverse interdisciplinary group of researchers to support future research in this area.

The research has provided insights into how ethnicity, social deprivation and other factors may influence the development and progression of MLTCs. It has also generated evidence on the relationship between MLTCs and hospital readmission and identified differences in the burden of multimorbidity across population groups.

 

Impact and outputs brochure